{
  "id": 5075,
  "text": "Revised FIGO Staging for carcinoma of the cervix uteri.Int J Gynecol Obstet 2019;145:129-135 及 Corrigendum to \"Revised FIGO Staging for carcinoma ofthe cervix uteri” [Int J Gynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Revised FIGO Staging for carcinoma of the cervix uteri.Int J Gynecol Obstet 2019;145:129-135 及 Corrigendum to \"Revised FIGO Staging for carcinoma ofthe cervix uteri” [Int J Gynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "2019年FIGO对宫颈癌的分期进行了修订，主要包括以下几点：\n\n1. 分期标准的具体化：FIGO更详细地定义了各分期的临床和影像学评估方法，以提高分期的准确性。\n\n2. 扩展影像学的使用：在分期过程中，建议使用CT、MRI以及PET扫描，这些影像学工具有助于明确肿瘤的局部侵犯和淋巴结的受累情况。\n\n3. 纳入淋巴结转移：淋巴结状态被纳入分期考虑中，这项变更反映了淋巴结转移对预后的重要影响。\n\n4. 调整分期阈值：某些分期的大小阈值和参数有所调整，以适应新的临床实证数据。\n\n通过这些修订，旨在提高宫颈癌分期的精确性和对患者预后评估的有效性，使医疗团队能够制定更合适的治疗方案。为患者提供更为个性化的治疗方法。",
  "query": "宫颈癌的FIGO分期在2019年进行了哪些修订？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 宫颈癌的FIGO分期在2019年进行了哪些修订？\n\n<reference text>: Revised FIGO Staging for carcinoma of the cervix uteri.Int J Gynecol Obstet 2019;145:129-135 及 Corrigendum to \"Revised FIGO Staging for carcinoma ofthe cervix uteri” [Int J Gynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "2019年FIGO对宫颈癌的分期进行了修订，主要包括以下几点：\n\n1. 分期标准的具体化：FIGO更详细地定义了各分期的临床和影像学评估方法，以提高分期的准确性。\n\n2. 扩展影像学的使用：在分期过程中，建议使用CT、MRI以及PET扫描，这些影像学工具有助于明确肿瘤的局部侵犯和淋巴结的受累情况。\n\n3. 纳入淋巴结转移：淋巴结状态被纳入分期考虑中，这项变更反映了淋巴结转移对预后的重要影响。\n\n4. 调整分期阈值：某些分期的大小阈值和参数有所调整，以适应新的临床实证数据。\n\n通过这些修订，旨在提高宫颈癌分期的精确性和对患者预后评估的有效性，使医疗团队能够制定更合适的治疗方案。为患者提供更为个性化的治疗方法。"
}